On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Hepatitis B
/ complications
Hepatitis C
/ complications
Humans
Immunosuppressive Agents
/ therapeutic use
Influenza, Human
/ complications
Neoplasms
/ complications
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Virus Diseases
/ complications
T-lymphocytes
immune evation
review
tumor escape
vaccination
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
accepted:
12
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
21
7
2020
Statut:
ppublish
Résumé
The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
Identifiants
pubmed: 32611687
pii: jitc-2020-001145
doi: 10.1136/jitc-2020-001145
pmc: PMC7358098
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: TG has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. JR and CHS declare that they have no competing interests. JCB is receiving speaker’s bureau honoraria from Amgen, Pfizer, Merck-Serono, Recordati and Sanofi, is a paid consultant/advisory board member for Boehringer Ingelheim, eTheRNA, In ProTher, MerckSerono, Pfizer, 4SC and Sanofi. His group receives research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis.
Références
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
AIDS. 2018 Jul 17;32(11):1491-1497
pubmed: 29746296
JAMA Netw Open. 2019 Nov 1;2(11):e1914816
pubmed: 31702796
J Clin Oncol. 2017 Nov 20;35(33):3774-3780
pubmed: 28968173
J Immunother Cancer. 2019 Feb 22;7(1):53
pubmed: 30795818
Immunotherapy. 2020 Apr;12(6):351-354
pubmed: 32290754
J Immunol. 2009 Jan 15;182(2):980-7
pubmed: 19124741
Thorac Cancer. 2020 Mar;11(3):799-804
pubmed: 32017466
J Clin Neuromuscul Dis. 2019 Jun;20(4):194-199
pubmed: 31135622
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Open Forum Infect Dis. 2019 Sep 30;6(10):ofz374
pubmed: 31660340
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Future Oncol. 2020 Jun;16(17):1153-1156
pubmed: 32323577
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1395-1396
pubmed: 32426877
Int J Infect Dis. 2017 Mar;56:221-228
pubmed: 28163164
J Neurovirol. 2019 Apr;25(2):284-287
pubmed: 30864100
JAMA Oncol. 2019 Jul 1;5(7):1049-1054
pubmed: 30730549
N Engl J Med. 2019 Apr 25;380(17):1597-1605
pubmed: 30969503
PLoS One. 2018 Jun 7;13(6):e0198158
pubmed: 29879143
Degener Neurol Neuromuscul Dis. 2019 Dec 02;9:109-121
pubmed: 31819703
J Infect Dis. 2017 Jun 1;215(11):1725-1733
pubmed: 28431010
Clin Infect Dis. 2020 Jul 11;71(2):422-425
pubmed: 31680143
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Clin Infect Dis. 2020 Mar 17;70(7):1519
pubmed: 31210266
J Hepatol. 2019 Nov;71(5):900-907
pubmed: 31306680
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
J Autoimmun. 2020 May;109:102442
pubmed: 32253068
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8
pubmed: 22549384
J Viral Hepat. 2020 Apr 27;:
pubmed: 32340080
Lancet Neurol. 2010 Apr;9(4):425-37
pubmed: 20298966
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32300051
Curr Opin HIV AIDS. 2019 Mar;14(2):121-128
pubmed: 30585798
Bioinformation. 2020 Mar 31;16(3):219-222
pubmed: 32308263
AIDS. 2007 Oct 1;21(15):2005-13
pubmed: 17885290
Immunotherapy. 2019 Apr;11(5):429-441
pubmed: 30698054
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Int J Infect Dis. 2020 May;94:74-77
pubmed: 32229257
Cancer Discov. 2020 May 12;:
pubmed: 32398243
Immunotherapy. 2020 Jun;12(8):545-548
pubmed: 32349579
Nature. 2016 Nov 3;539(7627):102-106
pubmed: 27749818
J Thorac Oncol. 2020 Jun;15(6):e83-e85
pubmed: 32243919
Cell Rep Med. 2020 May 19;1(2):100016
pubmed: 32562483
N Engl J Med. 2019 Apr 25;380(17):1667-1668
pubmed: 30969502
PLoS Pathog. 2012;8(5):e1002710
pubmed: 22615569
Medicine (Baltimore). 2020 Jan;99(5):e19013
pubmed: 32000444
Asia Pac J Clin Oncol. 2020 Aug;16(4):201-210
pubmed: 32212243
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
J Thorac Oncol. 2018 Dec;13(12):1930-1939
pubmed: 30267842
Cancer. 2017 Jun 1;123(11):1904-1911
pubmed: 28241095
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28544595
J Oncol Pharm Pract. 2020 Apr;26(3):647-654
pubmed: 31474214
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
ESMO Open. 2017 Jul 3;2(2):e000213
pubmed: 28761757
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
J Immunother Cancer. 2019 Dec 17;7(1):353
pubmed: 31847881
Cancer Treat Rev. 2020 Jun;86:102011
pubmed: 32213376
J Infect Dis. 1997 Jul;176(1):250-4
pubmed: 9207375
Oncologist. 2020 Feb;25(2):105-111
pubmed: 32043797
Clin Cancer Res. 2020 Jan 1;26(1):232-241
pubmed: 31624103
Virol Sin. 2018 Dec;33(6):467-471
pubmed: 30570713
PLoS One. 2013 May 22;8(5):e63818
pubmed: 23717490
PLoS Pathog. 2014 Jan;10(1):e1003856
pubmed: 24391505
J Transl Autoimmun. 2020 Apr 9;:100051
pubmed: 32292901
Retrovirology. 2015 Feb 08;12:14
pubmed: 25756928
Crit Rev Oncol Hematol. 2019 Jul;139:87-90
pubmed: 31112887
Emerg Infect Dis. 2019 Nov;25(11):2145-2147
pubmed: 31625858
Eur J Cancer. 2018 Nov;104:182-187
pubmed: 30368069
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
J Immunother Cancer. 2018 May 22;6(1):40
pubmed: 29789020
PLoS Pathog. 2016 Jul 14;12(7):e1005661
pubmed: 27415828
Clin Infect Dis. 2020 Jan 2;70(2):193-199
pubmed: 30874791
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Immunotherapy. 2018 Oct;10(14):1229-1239
pubmed: 30326787
PLoS Pathog. 2010 Jun 10;6(6):e1000947
pubmed: 20548953
JCO Oncol Pract. 2020 Jul;16(7):e573-e580
pubmed: 32048920
Lung Cancer. 2020 Jul;145:181-185
pubmed: 32423643
Genome Med. 2018 Sep 20;10(1):71
pubmed: 30236153
Chin Med J (Engl). 2020 May 5;133(9):1080-1086
pubmed: 32149773
Nat Immunol. 2007 Nov;8(11):1246-54
pubmed: 17906628
Front Immunol. 2020 Mar 04;11:401
pubmed: 32194573
Dig Dis. 2017;35(4):334-338
pubmed: 28468011
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S95-S107
pubmed: 29427804